Clicky

Myriad Genetics, Inc.(MYGN)

Description: Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. The company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels, and proteins to assess an individual's risk for developing disease later in life; determine a patient's likelihood of responding to a particular drug; and assess a patient's risk of disease progression and disease recurrence. It offers various molecular diagnostic tests that include BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; MELARIS predictive medicine test for hereditary melanoma; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized and prognostic medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and TheraGuide 5-FU, a personalized medicine test for drug toxicity. The company, through its subsidiary, Myriad RBM, Inc., also offers biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.


Keywords: Medicine Biotechnology Cancer Clinical Medicine Disease Prostate Cancer Melanoma Ovarian Cancer Biomarkers Colorectal Cancer Genetics Diagnostic Tests Medical Genetics Pancreatic Cancer Medical Research Multiplex Immunoassay Diagnostic Services Lab Testing Personalized Medicine Chemical Pathology Companion Diagnostic Whole Blood Breast And Ovarian Cancer Medical Signs Predictive Medicine Hereditary Breast Myriad Genetics Uterine Cancer

Home Page: myriad.com

MYGN Technical Analysis

320 Wakara Way
Salt Lake City, UT 84108
United States
Phone: 801 584 3600


Officers

Name Title
Mr. Paul J. Diaz CEO, Pres & Director
Mr. R. Bryan Riggsbee Exec. VP, CFO & Treasurer
Ms. Nicole Lambert Chief Operating Officer
Mr. Mark S. Verratti Chief Commercial Officer
Ms. Natalie Munk Principal Accounting Officer
Dr. Kevin Richard Haas Chief Technology Officer
Dr. Dale Muzzey Ph.D. Chief Scientific Officer
Mr. Scott Gleason Sr. VP of Investor Relations
Dr. Clivetty Martinez Chief Compliance Officer
Ms. Pamela Wong Chief Legal Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 40.9836
Trailing PE: 0
Price-to-Book MRQ: 1.6656
Price-to-Sales TTM: 2.1502
IPO Date: 1995-10-05
Fiscal Year End: June
Full Time Employees: 2400
Back to stocks